- A federal judge dismissed a whistleblower lawsuit accusing Novartis AG NVS of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.
- U.S. District Judge Kimba Wood dismissed the whistleblower lawsuit, arguing that former Novartis sales representative Steven Camburn did not provide enough detail to support his claims.
- Camburn's lawyer says he and his client plan to appeal the decision, adding that they're confident the ruling will be reversed, Reuters reports.
- Gilenya was the company's third-best-selling drug in 2021, bringing in $2.8 billion worldwide out of $51.6 billion in total sales.
- Camburn sued Novartis in 2013 under the False Claims Act, claiming that Novartis paid doctors up to $3,500 to participate as speakers in purportedly educational speaker events to induce them to prescribe and promote Gilenya.
- Novartis, in 2020, agreed to pay $729 million to settle similar whistleblower claims related to its speaker program and its diabetes and cardiovascular drugs.
- Price Action: NVS shares are down 1.55% at $80.68 on the last check Wednesday.
- Photo via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...